Geoffrey Appelboom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Geoffrey Appelboom has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
E. Sander Connolly
Department of Neurological Surgery, Cerebrovascular Laboratory, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA
9 shared publicationsBrian Y. Hwang
John Hopkins Department of Neurological Surgery, Baltimore, MD, USA
6 shared publicationsSamuel S. Bruce
Neurodigital Laboratory, Columbia University, Department of Neurological Surgery, 630 West 168th Street, New York, NY 10032, USA
4 shared publicationsMatthew Piazza
3 shared publicationsStephan Mayer
3 shared publicationsBlake Taylor
Department of Neurological Surgery, Cerebrovascular Laboratory, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA
2 shared publications
Latest Publications
- 1 December 2015
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 22 (12) , 1867-1870
The role of age in intracerebral hemorrhages
- 1 December 2015
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 22 (12) , 1867-1870
The role of age in intracerebral hemorrhages
- Open Access
- 28 July 2015
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 3 (3) , e78
Mobile Phone-Connected Wearable Motion Sensors to Assess Postoperative Mobilization
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.
- 28 July 2015
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 3 (3) , e78
Open AccessMobile Phone-Connected Wearable Motion Sensors to Assess Postoperative Mobilization
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.
- 1 March 2015
- Published by Elsevier in World Neurosurgery
- Vol. 83 (3) , 301-302
Age Selection for Decompressive Craniectomy in Malignant Middle Cerebral Artery Infarction
- 1 March 2015
- Published by Elsevier in World Neurosurgery
- Vol. 83 (3) , 301-302
Age Selection for Decompressive Craniectomy in Malignant Middle Cerebral Artery Infarction
- 25 November 2014
- Vol. 59 (1) , 73-8
Hemicraniectomy for malignant middle cerebral artery territory infarction: an updated review.
A decompressive hemicraniectomy is frequently performed for patients with malignant middle cerebral artery territory infarction (MMI) to reduce the intracranial hypertension, which may otherwise result in transtentorial herniation. However, certain clinically significant issues ‑ diagnostic criteria, predictors of the MMI clinical course, benefit of surgery in certain populations, timing of surgery ‑ are unresolved. In this article, we provide an updated review on the diagnosis and management of MMI. An extensive search of the PubMed, EMBASE, and Cochrane was conducted using varying combinations of the search terms, "hemicraniectomy," "decompressive craniectomy," "malignant middle cerebral artery territory infarction," "massive middle cerebral artery territory infarction," "massive ischemic stroke," "decompressive surgery," and "neurosurgery for ischemic stroke." Several large, randomized trials within the past decade have firmly established the benefit of decompressive hemicraniectomy (DHC) as a treatment of MMI. Further studies since then have not only better characterized the diagnosis and predictors of MMI, but have also shown that this benefit extends to patients with additional clinical and demographic characteristics. Future randomized studies should continue to evaluate the benefit of a DHC in other subgroups, and assess neurocognitive and psychosocial secondary outcomes.
- 25 November 2014
- Vol. 59 (1) , 73-8
Hemicraniectomy for malignant middle cerebral artery territory infarction: an updated review.
A decompressive hemicraniectomy is frequently performed for patients with malignant middle cerebral artery territory infarction (MMI) to reduce the intracranial hypertension, which may otherwise result in transtentorial herniation. However, certain clinically significant issues ‑ diagnostic criteria, predictors of the MMI clinical course, benefit of surgery in certain populations, timing of surgery ‑ are unresolved. In this article, we provide an updated review on the diagnosis and management of MMI. An extensive search of the PubMed, EMBASE, and Cochrane was conducted using varying combinations of the search terms, "hemicraniectomy," "decompressive craniectomy," "malignant middle cerebral artery territory infarction," "massive middle cerebral artery territory infarction," "massive ischemic stroke," "decompressive surgery," and "neurosurgery for ischemic stroke." Several large, randomized trials within the past decade have firmly established the benefit of decompressive hemicraniectomy (DHC) as a treatment of MMI. Further studies since then have not only better characterized the diagnosis and predictors of MMI, but have also shown that this benefit extends to patients with additional clinical and demographic characteristics. Future randomized studies should continue to evaluate the benefit of a DHC in other subgroups, and assess neurocognitive and psychosocial secondary outcomes.
- 1 July 2014
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 21 (7) , 1089-1093
The promise of wearable activity sensors to define patient recovery
- 1 July 2014
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 21 (7) , 1089-1093
The promise of wearable activity sensors to define patient recovery
- 1 November 2013
- Published by Elsevier in World Neurosurgery
- Vol. 80 (5) , 670-671
The Degree of Admission International Normalized Ratio Elevation Predicts Enlargement of Spontaneous Intracerebral Hematomas
- 1 November 2013
- Published by Elsevier in World Neurosurgery
- Vol. 80 (5) , 670-671
The Degree of Admission International Normalized Ratio Elevation Predicts Enlargement of Spontaneous Intracerebral Hematomas
- 1 November 2013
- Published by Elsevier in World Neurosurgery
- Vol. 80 (5) , e153-e155
Clinical Trials in Decompressive Craniectomy After Severe Diffuse Traumatic Brain Injury
- 1 November 2013
- Published by Elsevier in World Neurosurgery
- Vol. 80 (5) , e153-e155
Clinical Trials in Decompressive Craniectomy After Severe Diffuse Traumatic Brain Injury
- 17 December 2011
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 26 (2) , 189-194
Glioblastoma biomarkers from bench to bedside: advances and challenges
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour, with few available therapies providing significant improvements in mortality. Biomarkers, which are defined by the National Institutes of Health as ‘characteristics that are objectively measured and evaluated as indicators of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention’, have the potential to play valuable roles in the diagnosis and treatment of GBM. Although GBM biomarker research is still in its early stages because of the tumour's complex pathophysiology, a number of potential markers have been identified which can be measured in either brain tissue or blood serum. In conjunction with other clinical data, particularly neuroimaging modalities such as MRI, these proteins could contribute to the clinical management of GBM by helping to classify tumours, predict prognosis and assess treatment response. In this article, we review the current understanding of GBM pathophysiology and recent advances in GBM biomarker research, and discuss the potential clinical implications of promising biomarkers. A better understanding of GBM pathophysiology will allow researchers and clinicians to identify optimal biomarkers and methods of interpretation, leading to advances in tumour classification, prognosis prediction and treatment assessment.
- 17 December 2011
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 26 (2) , 189-194
Glioblastoma biomarkers from bench to bedside: advances and challenges
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour, with few available therapies providing significant improvements in mortality. Biomarkers, which are defined by the National Institutes of Health as ‘characteristics that are objectively measured and evaluated as indicators of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention’, have the potential to play valuable roles in the diagnosis and treatment of GBM. Although GBM biomarker research is still in its early stages because of the tumour's complex pathophysiology, a number of potential markers have been identified which can be measured in either brain tissue or blood serum. In conjunction with other clinical data, particularly neuroimaging modalities such as MRI, these proteins could contribute to the clinical management of GBM by helping to classify tumours, predict prognosis and assess treatment response. In this article, we review the current understanding of GBM pathophysiology and recent advances in GBM biomarker research, and discuss the potential clinical implications of promising biomarkers. A better understanding of GBM pathophysiology will allow researchers and clinicians to identify optimal biomarkers and methods of interpretation, leading to advances in tumour classification, prognosis prediction and treatment assessment.
- 1 November 2011
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 18 (11) , 1439-1443
Complement Factor H Y402H polymorphism is associated with an increased risk of mortality after intracerebral hemorrhage
- 1 November 2011
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 18 (11) , 1439-1443
Complement Factor H Y402H polymorphism is associated with an increased risk of mortality after intracerebral hemorrhage
- 1 July 2011
- Published by Wolters Kluwer Health in Stroke
- Vol. 42 (7) , 1883-1888
Severity of Intraventricular Extension Correlates With Level of Admission Glucose After Intracerebral Hemorrhage
Background and Purpose—: Hyperglycemia after spontaneous intracerebral hemorrhage (ICH) is associated with poor outcome, but the pathophysiology of ICH-induced glucose dysregulation remains unclear. We sought to identify clinical and radiographic parameters of ICH that are associated with admission hyperglycemia. Methods—: Patients admitted to the Columbia University Medical Center Neurological Intensive Care Unit with spontaneous ICH between January 2009 and September 2010 were prospectively enrolled in the ICH Outcomes Project. Clinical, radiographic, and laboratory data were collected prospectively. Receiver operating characteristic analysis was used to identify the glucose level with optimal sensitivity and specificity for in-hospital mortality. Logistic and linear regression analyses were used to identify independent predictors of outcome measures where appropriate. Results—: One hundred four patients admitted during the study period were included in the analysis. Mean admission glucose level was 8.23±3.15 mmol/L (3.83 to 18.89 mmol/L) and 23.2% had a history of diabetes mellitus. Admission glucose was significantly associated with discharge ( P =0.003) and 3-month mortality ( P =0.002). Critical hyperglycemia defined at 10 mmol/L independently predicted discharge mortality ( P =0.027; OR, 4.381; 95% CI, 1.186 to 16.174) and 3-month mortality ( P =0.011; OR, 10.95; 95% CI, 1.886 to 62.41). Admission intraventricular extension score ( P =0.038; OR, 1.117; 95% CI, 1.043 to 1.197) and diabetes mellitus ( P =0.002; OR, 5.530; 95% CI, 1.833 to 16.689) were independent predictors of critical hyperglycemia. The intraventricular extension score (B=0.115, P =0.001) linearly correlated with admission glucose level ( R =0.612, P =0.001) after adjusting for other clinical variables. Conclusions—: Admission hyperglycemia after spontaneous ICH is associated with poor outcome and potentially related to the presence and severity of intraventricular extension.
- 1 July 2011
- Published by Wolters Kluwer Health in Stroke
- Vol. 42 (7) , 1883-1888
Severity of Intraventricular Extension Correlates With Level of Admission Glucose After Intracerebral Hemorrhage
Background and Purpose—: Hyperglycemia after spontaneous intracerebral hemorrhage (ICH) is associated with poor outcome, but the pathophysiology of ICH-induced glucose dysregulation remains unclear. We sought to identify clinical and radiographic parameters of ICH that are associated with admission hyperglycemia. Methods—: Patients admitted to the Columbia University Medical Center Neurological Intensive Care Unit with spontaneous ICH between January 2009 and September 2010 were prospectively enrolled in the ICH Outcomes Project. Clinical, radiographic, and laboratory data were collected prospectively. Receiver operating characteristic analysis was used to identify the glucose level with optimal sensitivity and specificity for in-hospital mortality. Logistic and linear regression analyses were used to identify independent predictors of outcome measures where appropriate. Results—: One hundred four patients admitted during the study period were included in the analysis. Mean admission glucose level was 8.23±3.15 mmol/L (3.83 to 18.89 mmol/L) and 23.2% had a history of diabetes mellitus. Admission glucose was significantly associated with discharge ( P =0.003) and 3-month mortality ( P =0.002). Critical hyperglycemia defined at 10 mmol/L independently predicted discharge mortality ( P =0.027; OR, 4.381; 95% CI, 1.186 to 16.174) and 3-month mortality ( P =0.011; OR, 10.95; 95% CI, 1.886 to 62.41). Admission intraventricular extension score ( P =0.038; OR, 1.117; 95% CI, 1.043 to 1.197) and diabetes mellitus ( P =0.002; OR, 5.530; 95% CI, 1.833 to 16.689) were independent predictors of critical hyperglycemia. The intraventricular extension score (B=0.115, P =0.001) linearly correlated with admission glucose level ( R =0.612, P =0.001) after adjusting for other clinical variables. Conclusions—: Admission hyperglycemia after spontaneous ICH is associated with poor outcome and potentially related to the presence and severity of intraventricular extension.